All News

New research examines the mechanisms underlying why most patients with high-grade serous ovarian cancer develop resistance to PARP inhibitors.

Linda Jacobs, PhD, CRNP, director of the Cancer Survivorship Center, comments on the incidence of erectile dysfunction in childhood cancer survivors.

Researchers have developed a mouse model of high-grade serous carcinoma that could prove useful in the preclinical testing of prevention strategies for ovarian cancer.

Optical coherence tomography and multispectral fluorescence imaging have demonstrated promising results in the early detection of ovarian cancer.

Breast and gynecologic cancer patients undergoing chemotherapy may experience improvement in cancer-related fatigue with integrative medicine approaches.

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

A particular gatekeeper-the nuclear pore protein called POM121-traffics molecules that increase tumor aggressiveness in prostate cancer.

A study finds EWSR1-ETS in 42% of cases via complex, loop-like rearrangements, rather than by simple reciprocal translocations.

Mogamulizumab (Poteligeo) is indicated for relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy.

A study shows significant association between MTHFR C677T polymorphisms and risk of oral squamous cell carcinoma.

The number of nurse practitioners and physician assistants in oncology is growing, according to a new study.

The guidelines will better ensure pregnant cancer patients receive life-saving treatment while preserving fertility.

For patients undergoing primary treatment for head and neck cancer, sexuality was significantly impacted in many patients both prior to and during cancer treatment.

VOC breath tests have potential, but more guidance, standardization are needed.

A retrospective study shows that undergoing oral care prior to cancer surgery decreased postoperative complications.

Cancer patients with a documented history of depressive symptoms prior to hospital admission experience an extended hospital stay.

Targeted delivery of nanoparticles may reduce systemic and CNS toxicity in spinal cord tumors.

Study shows that ctDNA levels measured by targeted deep sequencing sensitively indicate the presence of cancer.

A study shows that LKB1 deficiency in T cells increases gastrointestinal polyposis development.

Oncologists should refer patients who want traditional genetic counseling and/or have preexisting psychosocial factors that would increase risk of an adverse psychological outcome of counseling.

In analyzing over 8,300 mosaic chromosomal alterations in UK Biobank participants, Harvard researchers uncovered specific alterations that may predict for CLL.

Brazilian researchers say their study results “suggest the overall DNA methylation profile may be influenced by the histological subtype of thyroid cancer.”

Strong efficacy and safety outcomes with this agent, which targets the molecular driver of an AML subset, have led to its approval in IDH1-mutated R/R disease.

Oncologist Dr. Vivek Subbiah and computer scientist Dr. Jason Roszik, both from MD Anderson, discuss optimizing “omics” databases to inform cancer patient care.

In an exclusive interview, thyroid cancer expert and surgeon Dr. Louise Davies discusses overdiagnosis and overtreatment of subclinical thyroid cancers.

A team of Texas-based oncologists says their preclinical study results “demonstrate that IGF-1R and FOXC1 seem to positively regulate each other.”

FDA, CMS, and Department of Veterans Affairs experts will be included. Dr. Robin Zon, a past chair of ASCO’s Government Relations Committee, said it is “critical” that the FDA work with providers and patients.

In an interview with Cancer Network, Lorraine Drapek describes a multidisciplinary program at MGH to support vaginal and sexual health post RT for GI and gynecologic malignancies.

A noncontrolled phase I study in recurrent metastatic glioblastoma showed 3-year survival was five times higher in patients treated with intratumoral PVSRIPO.

In a phase I trial, this first-in-class novel drug yielded a 71% response rate in very high expressers of PD-L1 treated at 1,200 mg every 2 weeks.